MARKET

ONTX

ONTX

Onconova
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.840
-0.030
-1.60%
Closed 19:47 01/26 EST
OPEN
1.910
PREV CLOSE
1.870
HIGH
1.947
LOW
1.800
VOLUME
116.08K
TURNOVER
--
52 WEEK HIGH
28.95
52 WEEK LOW
1.690
MARKET CAP
38.44M
P/E (TTM)
-1.3862
1D
5D
1M
3M
1Y
5Y
Jazz Pharma (JAZZ) Begins Zepzelca Confirmatory Study for SCLC
Zacks.com · 12/14/2021 15:50
We're Not Very Worried About Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 12/06/2021 13:35
Onconova Therapeutics Announces The Presentation Of Preliminary Clinical Data Providing Evidence Of Rigosertib's Activity In RDEB-associated Squamous Cell Carcinoma
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that early preliminary data from an
Benzinga · 12/02/2021 13:05
Onconova Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
NEWTOWN, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be p...
GlobeNewswire · 11/22/2021 13:00
BRIEF-Onconova Therapeutics Reports Third Quarter 2021 Financial Results And Provides Business Update
reuters.com · 11/11/2021 22:04
Recap: Onconova Therapeutics Q3 Earnings
Onconova Therapeutics (NASDAQ:ONTX) reported its Q3 earnings results on Thursday, November 11, 2021 at 04:00 PM. Here's what investors need to know about the announcement.
Benzinga · 11/11/2021 21:30
Onconova Therapeutics Q3 EPS $(0.22) Beats $(0.33) Estimate
Onconova Therapeutics (NASDAQ:ONTX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.33) by 33.33 percent. This is a 51.11 percent increase over losses of $(0.45) per share
Benzinga · 11/11/2021 21:04
Onconova Therapeutics EPS beats by $0.11, beats on revenue
Onconova Therapeutics (NASDAQ:ONTX): Q3 GAAP EPS of -$0.22 beats by $0.11. Revenue of $0.06M (-14.3% Y/Y) beats by $0.01M. Press Release Cash and cash equivalents as of September 30, 2021,
Seekingalpha · 11/11/2021 21:02
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ONTX. Analyze the recent business situations of Onconova through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
33.33%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ONTX stock price target is 11.50 with a high estimate of 12.00 and a low estimate of 11.00.
High12.00
Average11.50
Low11.00
Current 1.840
EPS
Actual
Estimate
-0.42-0.32-0.21-0.11
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 56
Institutional Holdings: 4.10M
% Owned: 19.65%
Shares Outstanding: 20.89M
TypeInstitutionsShares
Increased
8
223.44K
New
18
1.21M
Decreased
8
183.53K
Sold Out
6
101.76K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.38%
Pharmaceuticals & Medical Research
-0.45%
Key Executives
Non-Executive Chairman/Independent Director
James Marino
President/Chief Executive Officer/Director
Steven Fruchtman
Chief Financial Officer
Mark Guerin
Senior Vice President/General Counsel
Abraham Oler
Other
Mark Gelder
Independent Director
Jerome Groopman
Independent Director
Viren Mehta
Independent Director
M. Teresa Shoemaker
Independent Director
Jack Stover
No Data
About ONTX
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

Webull offers kinds of Onconova Therapeutics Inc stock information, including NASDAQ:ONTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONTX stock methods without spending real money on the virtual paper trading platform.